Literature DB >> 12358929

Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.

Nicholas P Connolly1, Margaret Jones, Suzanne M Watt.   

Abstract

Human Siglec-5 is a sialic acid binding immunoglobulin (Ig)-like lectin (Siglec), comprising one N-terminal IgV-SET domain followed by three IgC2-SET domains, and a cytoplasmic domain with ITIM and SAP motifs which regulate cell signalling. We report the differential distribution of hSiglec-5 on neutrophil and macrophage subsets in tissues using monoclonal antibodies, 1A5 and 2H8, which require the first IgC2-SET domain for binding. Interestingly, hSiglec-5 was especially prominent on macrophages in reactive lymph nodes. We have identified four isoforms of hSiglec-5 possessing three (hSiglec-5-3L and -3C) or four (hSiglec-5-4L and -4S) extracellular domains linked to long (hSiglec-5-3L and -4L) or short (hSiglec-5-4S) cytoplasmic tails or existing as a soluble isoform (hSiglec-5-3C). hSiglec-5-4L has the broadest tissue distribution, being detected in adult spleen, thymus, lymph node, peripheral blood leucocytes and bone marrow, and in fetal lung and liver. A soluble Fc chimaeric protein containing the hSiglec-5-4L extracellular domain binds in a sialic acid-dependent manner to glycophorin A on human erythrocytes and to alpha2-3- and alpha2-6-sialyllactose moieties. Domain deletion mutants of hSiglec-5(D1-4)-Fc reveal that the first three IgC2-SET domains are required for optimal binding, with adhesion being abolished if the first IgC2-SET domain is deleted. This indicates that each hSiglec-5 isoform will interact with sialic acid ligands and provides the first step towards defining structure-function relationships of hSiglec-5 isoforms.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12358929     DOI: 10.1046/j.1365-2141.2002.03808.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  The structure of siglec-7 in complex with sialosides: leads for rational structure-based inhibitor design.

Authors:  Helen Attrill; Hirokazu Takazawa; Simone Witt; Soerge Kelm; Rainer Isecke; Reinhard Brossmer; Takayuki Ando; Hideharu Ishida; Makoto Kiso; Paul R Crocker; Daan M F van Aalten
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

Review 2.  Basic and clinical immunology of Siglecs.

Authors:  Stephan von Gunten; Bruce S Bochner
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

3.  Structural implications of Siglec-5-mediated sialoglycan recognition.

Authors:  Marina A Zhuravleva; Kathryn Trandem; Peter D Sun
Journal:  J Mol Biol       Date:  2007-10-11       Impact factor: 5.469

4.  Soluble Siglec-14 glycan-recognition protein is generated by alternative splicing and suppresses myeloid inflammatory responses.

Authors:  Po-Chun Jimmy Huang; Penk-Yeir Low; Iren Wang; Shang-Te Danny Hsu; Takashi Angata
Journal:  J Biol Chem       Date:  2018-10-30       Impact factor: 5.157

Review 5.  Molecular diversity and evolution of the Siglec family of cell-surface lectins.

Authors:  Takashi Angata
Journal:  Mol Divers       Date:  2006-11       Impact factor: 3.364

6.  Soluble Siglec-5 associates to PSGL-1 and displays anti-inflammatory activity.

Authors:  Marion Pepin; Soraya Mezouar; Julie Pegon; Vincent Muczynski; Frédéric Adam; Elsa P Bianchini; Amine Bazaa; Valerie Proulle; Alain Rupin; Jerome Paysant; Laurence Panicot-Dubois; Olivier D Christophe; Christophe Dubois; Peter J Lenting; Cécile V Denis
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 7.  To clear or to fear: An innate perspective on factor VIII immunity.

Authors:  Jesse Derek Lai; Maria Teofana Georgescu; Christine Hough; David Lillicrap
Journal:  Cell Immunol       Date:  2015-10-28       Impact factor: 4.868

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.